833 related articles for article (PubMed ID: 11119690)
1. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
[TBL] [Abstract][Full Text] [Related]
3. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
4. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
5. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
6. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Eberhardt O; Coelln RV; Kugler S; Lindenau J; Rathke-Hartlieb S; Gerhardt E; Haid S; Isenmann S; Gravel C; Srinivasan A; Bahr M; Weller M; Dichgans J; Schulz JB
J Neurosci; 2000 Dec; 20(24):9126-34. PubMed ID: 11124990
[TBL] [Abstract][Full Text] [Related]
7. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
Mandel RJ; Spratt SK; Snyder RO; Leff SE
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14083-8. PubMed ID: 9391156
[TBL] [Abstract][Full Text] [Related]
8. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
9. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.
Kirik D; Rosenblad C; Bjorklund A; Mandel RJ
J Neurosci; 2000 Jun; 20(12):4686-700. PubMed ID: 10844038
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
[TBL] [Abstract][Full Text] [Related]
11. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
13. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
Georgievska B; Kirik D; Rosenblad C; Lundberg C; Björklund A
Neuroreport; 2002 Jan; 13(1):75-82. PubMed ID: 11924898
[TBL] [Abstract][Full Text] [Related]
17. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
18. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
19. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
[TBL] [Abstract][Full Text] [Related]
20. Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease.
Ge G; Chen C; Guderyon MJ; Liu J; He Z; Yu Y; Clark RA; Li S
Stem Cells Dev; 2018 Jul; 27(14):995-1005. PubMed ID: 29562865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]